Acne Treatment Innovation
Glenmark Launches Winlevi Across Europe, First New Topical Acne Therapy in Over 40 Years
Key Points
The European Commission authorization granted for Winlevi specifies that adolescents aged 12 to <18 can use it, but “usage in adolescents [is] limited to facial application.”
Glenmark characterized the European rollout as its “first New Chemical Entity (NCE) launch in Europe,” underscoring the product’s novelty within its regional pipeline.
Cosmo (via its announcement) cited detailed acne prevalence figures—“more than 95% of males and 85% of females” experience acne during adolescence, with “fifty percent” continuing to experience it in adulthood—alongside the condition’s physical and psychological impact on young people.
Glenmark’s stock reaction was reported with specific trading figures: shares were “₹2,151.80, up 0.35% as of 11:53 IST on June 11, 2026,” as investors assessed its ongoing move into specialty dermatology therapies and Europe expansion.
Cosmo added that because clascoterone acts locally in sebaceous glands and avoids systemic anti-androgen effects, it “support[s] safe use in both males and female” patients.
Glenmark Specialty S.A. has launched Winlevi — a clascoterone 10 mg/g cream — across key European markets, marking the first new class of topical acne therapy in more than 40 years. The cream works by blocking androgen receptors directly in the skin's oil glands, cutting sebum production without affecting hormones elsewhere in the body, according to Cosmo Pharmaceuticals.
The European Commission granted marketing authorization in October 2025 for adults and adolescents aged 12 and older. Glenmark's parent company called it their "first New Chemical Entity launch in Europe," a milestone that pushed shares to ₹2,151.80 — up 0.35% — by mid-morning on June 11, per HDFC Sky.
A 40-Year Gap in Acne Treatment Finally Closes
Before Winlevi, dermatologists relied on the same four tool categories since the 1980s: retinoids, benzoyl peroxide, antibiotics, and salicylic acid. Oral drugs like spironolactone could target hormonal acne, but only in female patients — their systemic anti-androgen effects made them unsafe for males. Clascoterone changes that equation entirely.
By acting locally in sebaceous glands — the tiny oil-producing structures in skin — the cream avoids the body-wide hormonal disruption of older drugs. Cosmo Pharmaceuticals said this means the treatment "supports safe use in both males and females," a first for hormone-targeting acne therapy. Cosmo is the exclusive manufacturer and holds the intellectual property through its Cassiopea subsidiary.
Adolescent Acne Affects Hundreds of Millions Worldwide
The scale of the problem Winlevi targets is enormous. More than 95% of males and 85% of females experience acne during adolescence, according to Cosmo Pharmaceuticals. Fifty percent of those patients continue to have acne in adulthood. Beyond the physical symptoms, the company stressed the condition's well-documented psychological toll on young people.
European regulators approved use in patients as young as 12. However, the European Medicines Agency drew one key line: adolescents under 18 may only apply the cream to the face. Regulators imposed that restriction to limit the risk of systemic absorption through younger skin — a concern that is downplayed in corporate marketing but spelled out in the product's regulatory summary.
Glenmark Goes Direct in Spain and the Nordics
Glenmark is not relying on licensing royalties for this launch. The company is commercializing Winlevi directly in Spain, Denmark, Norway, Sweden, Finland, and Central and Eastern Europe. That means it keeps a larger share of revenue per unit sold compared with traditional partnership models, according to Whalesbook.
In Portugal, Glenmark is using a strategic partner instead. The company is also pursuing additional partnership-led launches in other European countries — with markets like the UK, France, and Germany potentially next. Chairman Glenn Saldanha framed the milestone clearly: "The launch of Winlevi represents our first NCE launch in Europe," signaling a deliberate move away from low-margin generics toward specialty drugs, per HDFC Sky.
Investors See a Specialty Pivot, Not Just a Skin Cream
Glenmark's stock reaction was modest but positive. Shares rose 0.35% to ₹2,151.80 on the National Stock Exchange within hours of the announcement on June 11, 2026. Analysts view the move as part of a broader strategic shift — away from price-eroded U.S. generics and toward high-margin specialty drugs in regulated European markets.
The first-in-class status of clascoterone lets Glenmark set premium prices in a segment long dominated by cheap generics. Cosmo Pharmaceuticals welcomed the launch, noting it addresses "a massive unmet need" in the European population. As the exclusive manufacturer, Cosmo stands to benefit alongside Glenmark as the rollout expands across the continent.
Sentiment
Mostly PositivePublishers
11
Articles
19
Reach
30
